CD8A and neoplasm: They conjugated Abx using CREKA peptide that binds to clotted plasma proteins in tumor blood vessels or LyP-1 peptide (CGNKRTRGC) that binds to p32 overexpressed on tumor cells; the CREKA- or LyP-1-guided Abx led to a significant inhibition of tumor growth compared to untargeted Abx 46.